Obexelimab
Based on 1 Customer Validation
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.99%
- CAS 番号: 1690307-05-1
- 分子量:147.24 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD19
体外実験
Obexelimab can induce the expression levels of apoptosis pathway related genes and promote B cell apoptosis[1]. Obexelimab (10 μg/mL, 3 min) inhibits B cell activation and function by suppressing BCR mediated calcium flux and promoting Fc γ RIIb phosphorylation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B cells isolated from PBMC of healthy and RA donors
-
Concentration:10 μg/mL
-
Incubation Time:3 min
-
Result:Stimulated FcγRIIb phosphorylation in healthy and RA B cells.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C.B-17 SCID mice transplanted with PBMCs[2].
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.); twice a week
-
Result:Resulted in inhibition of various immune responses in mice, including IgG, IgM, RF, ACPA, and anti-tetanus antibodies.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling CD19 (red) with Obexelimab (HY-P99761). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Obexelimab. The EC50 for this effect is 16.38 ng/mL. -
Loaded Obexelimab on AHC2 biosensor, can bind CD19 Protein, Human (HEK293, His, HY-P74330) with an affinity constant of 1.556E-09 M as determined in BLI assay.
化学情報
-
CAS 番号 1690307-05-1
-
性状 Liquid
-
分子量 147.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Obexelimab]
-
別名
XmAb5871
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Boyles JS, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023 Jul 10;8(13):e166137. [Content Brief]
[2]. Chu SY, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014 May;66(5):1153-64. [Content Brief]
[3]. Horton HM, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1;186(7):4223-33. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)